Homocysteine and cardiovascular risk: The perils of reductionism in a complex system

Clinical Chemistry

Volumn 58, Issue 12, 2012, Pages 1623-1625

  Ueland, Per Magne ^a,b   Loscalzo, Joseph ^c  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; 5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BETAINE; CHOLESTEROL; CYANOCOBALAMIN; CYSTATHIONINE BETA SYNTHASE; FOLIC ACID; HOMOCYSTEINE; NITRIC OXIDE; S ADENOSYLHOMOCYSTEINE; VITAMIN B GROUP;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL PROLIFERATION; CORONARY ARTERY DISEASE; DISEASE COURSE; DNA SYNTHESIS; DYSLIPIDEMIA; ENZYME ACTIVITY; GENETIC DISORDER; GENOTYPE; HUMAN; HYPERTENSION; KIDNEY DISEASE; OXIDATIVE STRESS; PATHOGENESIS; PRIMARY PREVENTION; PROTEIN PROCESSING; REVIEW; SEDENTARY LIFESTYLE; THROMBOSIS; VASCULARIZATION; VITAMIN SUPPLEMENTATION;

ANIMALS; CORONARY DISEASE; DIETARY SUPPLEMENTS; FOLIC ACID; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMORPHISM, GENETIC; RISK; VITAMIN B COMPLEX;

EID: 84870369680     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2012.187286     Document Type: Review

References (6)

1. Joseph J, Handy DE, Loscalzo J. Quo vadis: whither homocysteine research? Cardiovasc Toxicol 2009;9:53-63.
2. Smulders YM, Blom HJ. The homocysteine controversy. J Inherit Metab Dis 2011;34:93-9.
3. Ebbing M, Ueland PM. Prevention: B vitamins and CVD - failure to find a simple solution. Nat Rev Cardiol 2010;7:608-9.
4. Clarke R, Bennett DA, Parish S, Verhoef P, Dotsch-Klerk M, Lathrop M, et al. Homocysteine and coronary heart disease: meta-analysis of MTHFR casecontrol studies, avoiding publication bias. PLoS Med 2012;9:e1001177.
5. Smith D, Hornstra J, Kok R, Blom H, Smulders Y. Folic acid supplementation may disturb the regulatory effect of S-adenosylmethionine on methylenetetrahydrofolatereductase activity [Abstract]. Clin Chem Lab Med 2012;50:A33.
6. Loscalzo, J. Personalized cardiovascular medicine and drug development: time for a new paradigm. Circulation 2012;125:635-45.